Bayer A, Ferrari F, Maren T H, Erb C
Department of Ophthalmology, Mount Sinai Medical Center, New York City, USA.
J Fr Ophtalmol. 1996;19(5):357-62.
Systemically administered carbonic anhydrase inhibitors have been in clinical use since the 1950's. Their use and side effects have been reviewed extensively. Our review summarizes the development of topically administered carbonic anhydrase inhibitors in patients with glaucoma. Moreover, it documents clinical trials leading to the present choice of dorzolamide (MK-507), which is now being reviewed for worldwide approval for marketing by 1995.
自20世纪50年代以来，全身给药的碳酸酐酶抑制剂一直在临床中使用。它们的用途和副作用已得到广泛综述。我们的综述总结了局部应用碳酸酐酶抑制剂在青光眼患者中的发展情况。此外，它记录了导致目前选择多佐胺（MK - 507）的临床试验，该药物目前正接受审评，有望在1995年获得全球上市批准。
